Justification (Sole Source)Posted Jan 6, 2025

6505--F-18 PSMA Pylarify

Veterans Affairs · 246-NETWORK CONTRACTING OFFICE 6 (36C246)

Stage
Justification for other than full competition
NAICS
325412
Value
$6.0M
Solicitation
36C24625R0016
Set-aside
None stated
PSC
6505
Place
Not stated
Contact
Daniel Spaulding (daniel.spaulding@va.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 36C24625R0016 in this department, oldest first.

Early notice
  • Dec 6, 2024
    Special Notice
    Open
Solicitation
None posted
Award
  • Jan 6, 2025
    Award Notice
    PROGENICS PHARMACEUTICALS INC · $6.0M
    Open
Other notices
  • Jan 6, 2025 · this notice
    Justification (Sole Source)
    PROGENICS PHARMACEUTICALS INC · $6.0M

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • The agency intends to buy without full competition. Read the justification for the reason and the named source.

What the notice says

This action is a new requirement to procure F-18 Pylarify (piflufolastat or 18F-DCFPyl) radiopharmaceutical for deliveries to be made to the Durham VA Medical Center located at 508 Fulton Street, Durham, North Carolina 27705. An open market Indefinite Delivery Indefinite Quantity contract (IDIQ) will be awarded with a one-year base period and three (3) one-year option periods. The period of performance will be from January 1, 2025 through December 31, 2025 for the base period of the contract. The total estimated value of this action, including the base period and all option periods, is $[REDAC… (show all)

TED]. The NAICS code for this action is 325412, Pharmaceutical Preparation Manufacturing with a size standard of 1300 employees. The manufacturer, PROGENICS PHARMACEUTICALS INC (UEI: YLYKVRPCTCR3), is the only source for F-18 Pylarify. PROGENICS PHARMACEUTICALS INC (UEI: YLYKVRPCTCR3) is a small business under NAICS 325412 with less than 1300 employees.

Who won similar work

6 award notices on SAM.gov in the last 24 months. Matched by: Same office (246-NETWORK CONTRACTING OFFICE 6 (36C246)), same product/service code (PSC) 6505 and NAICS 325412.

Single-winner award sizes (6): middle half $1.8M to $3.9M, median $2.0M; range $1.2M to $5.1M.

WinnerAwardsValueLast
PROGENICS PHARMACEUTICALS INC3$10.8MAug 5, 2026
CARDINAL HEALTH 414, LLC · $CAH · $254.2B2$3.8MNov 20, 2025
PETNET SOLUTIONS, INC.1$1.9MNov 6, 2025

Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.

Investor context
  • $CAH reported $254.2B revenue (fiscal year ending Jun 30, 2026). The median single-winner award in these 6 past awards, $2.0M, is under 0.1% of that. SEC filing

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards
  • Aug 5, 2026PROGENICS PHARMACEUTICALS INC$4.5M6505--PYLARIFY IMAGING AGENTNo listed company matched (Materiality N/A)
  • Nov 20, 2025CARDINAL HEALTH 414, LLC$1.7M6505--Standard Radiopharmaceuticals and SuppliesMateriality: <0.01% of $CAH revenue (Low) SEC
  • Nov 6, 2025PETNET SOLUTIONS, INC.$1.9M6505--PET Radiopharmaceuticals Award Notice at Durham VAMCNo listed company matched (Materiality N/A)
  • Oct 7, 2025CARDINAL HEALTH 414, LLC$2.1M6505--RADIOPHARMACEUTICALSMateriality: <0.01% of $CAH revenue (Low) SEC
  • Aug 25, 2025PROGENICS PHARMACEUTICALS INC$1.2M6505--Pylarify F-18 InjectionsNo listed company matched (Materiality N/A)
  • Feb 4, 2025PROGENICS PHARMACEUTICALS INC$5.1M6505--Pylarify InjectionsNo listed company matched (Materiality N/A)

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (0 filings)
  • 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
  • $45K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 25 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 1 of the past winners are listed companies
  • 0 insider buys and 7 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.